title: An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
abstract: BACKGROUND
  The European Consensus Programme (ECP) established pan-European consensus definitions of psoriasis disease severity and treatment goals among 19 psoriasis experts from European nations.
  
  
  OBJECTIVE
  To use the ECP treatment goals to retrospectively assess adalimumab efficacy in patients who participated in Phase III clinical trials and met ECP criteria for moderate to severe psoriasis.
  
  
  METHODS
  Three trials were analysed: CHAMPION (n = 108), REVEAL (n = 814) and BELIEVE (n = 364). Moderate to severe psoriasis was defined as Dermatology Life Quality Index (DLQI) score > 10, with either > 10% body surface area involvement or Psoriasis Area and Severity Index (PASI) score > 10. Treatment goals were achieved with either treatment success (≥ 75% PASI score reduction) or intermediate response (PASI response ≥ 50% and < 75%) with DLQI ≤ 5.
  
  
  RESULTS
  The percentages of patients who achieved treatment goals at week 16 in CHAMPION, REVEAL and BELIEVE were, respectively, (i) treatment success, 79·3%, 72·1% and 68·2%; (ii) intermediate response, 1·7%, 5·0% and 5·0%; or (iii) either goal, 81·0%, 77·1% and 73·2%. DLQI ≤ 5 at week 16 was achieved by 70·7%, 70·1% and 67·4% of patients, respectively. Differences between the percentages of adalimumab- vs. placebo-treated patients achieving treatment success were statistically significant (P < 0·001) from week 4 and week 8 of REVEAL and CHAMPION, respectively.
  
  
  CONCLUSIONS
  Treatment success was achieved by > 93% of patients who attained treatment goals. At week 16 > 70% of patients achieved ECP treatment goals and met ECP criteria for continued treatment without modification. These results support the utility of ECP treatment goals for the assessment of therapeutic efficacy in moderate to severe psoriasis.
authors.affiliation: Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. umrowietz@dermatology.uni-kiel.de
authors.forename: U
authors.initials: U
authors.lastname: Mrowietz
authors.forename: K
authors.initials: K
authors.lastname: Kragballe
authors.forename: K
authors.initials: K
authors.lastname: Reich
authors.forename: C E M
authors.initials: CE
authors.lastname: Griffiths
authors.forename: Y
authors.initials: Y
authors.lastname: Gu
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: S J
authors.initials: SJ
authors.lastname: Rozzo
mesh_terms: D006801:Humans; D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D006040:Goals; D011565:Psoriasis / Q000188:drug therapy / Q000628:therapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome; D003245:Consensus Statements as Topic
chemical_list: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents